# name
Genomics and epigenomics of substance use disorders: An introduction

# metadata.dc.description.abstract[].value
Substance use disorders (SUD) are common conditions around theworld, with important health and societal impacts, particularly inthe burden of disease (disability-adjusted life years) (Whiteford, Fer-rari, Degenhardt, Feigin, & Vos, 2015). The Global Burden of DiseaseStudy estimated the global number of cases for SUD for several sub-stances as follows: 94.8 million for alcohol, 17.2 million for amphet-amine, 15.5 million for opioids, and 13.1 million for cannabis(Whiteford, 2015). In the United States, the lifetime and 12-monthprevalences of SUD were 9.9% and 3.9%, respectively (Grantet al., 2016). In addition, polysubstance use is an important challengein the field of addiction research (Whiteford et al., 2015).

# metadata.dc.relation.ispartof[].value
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, vol. 186, num. 3, p. 125-127

# metadata.dc.source[].value
Articles publicats en revistes (Genètica, Microbiologia i Estadística)

# metadata.dc.title[].value
Genomics and epigenomics of substance use disorders: An introduction